RSS   Newsletter   Contact   Advertise with us

iOnctura appoints Joanna Horobin as chair

Christian Fernsby | Geneva, Switzerland | May 27, 2020
iOncturaiOnctura, a clinical stage biopharmaceutical company, announced that it has appointed Joanna Horobin as non-executive chair to the iOnctura board.
Dr. Horobin joined the pharma industry, first at Beecham Pharmaceuticals (now GSK), in 1982.

Whilst at Rhone Poulenc Rorer (now Sanofi), in France and USA, she shifted to cancer drug development which has been her major career focus.

She led a joint venture between Rhone Poulenc and Chugai to develop and launch Chugai's gCSF product Granocyte in Europe and, as VP Oncology, launched Rhone Poulenc Rorer as a major player in oncology with the global launch of Taxotere.

Dr. Horobin gained her medical qualifications from the University of Manchester Medical School in the United Kingdom.

She serves as a Non-Executive Director on the boards of Nordic Nanovector ASA, Liquidia Technologies Inc. and privately held Kymera Therapeutics Inc.